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Abstract Tau protein kinase II (TPKII) is shown by immunoprecipitation to be a complex composed of two subunits, a catalytic subunit, cdk5, 
and regulatory subunit, ~23. By sequence analysis of p23 cDNA, p23 was found to occupy a region from the 99th amino acid residue to the C-terminus 
of a novel protein with a molecular weight of 34,000 Da, suggesting that this 34 kDa protein is a precursor of p23 (pre-p23). These 8ndings suggest 
that p23 results from the processing of the precursor protein, pre-p23. The precursor mRNA was expressed most abundantly in rat brain just before 
and after birth. Expression of pre-p23, but not of cdk5, mRNA changed, coinciding with the developmental change of TPIUI activity, suggesting 
that its expression controls the phosphorylation f tau by the TPKIUTPKI system in the neonatal brain. p23 appears to he a cdk5 activator in 
neuronal cells. 
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1. Introduction 
Paired helical filaments (PHF) are one of the hallmarks of 
the brain of Alzheimer’s disease patients. PHF contain abnor- 
mally phosphorylated tau protein, reflecting the physiological 
state in the brain of an Alzheimer’s disease patients. It is impor- 
tant to determine the protein kinase responsible for the phos- 
phorylation in order to understand the etiology of the disease. 
Tau protein kinases (TPK) I and II (EC 2.7.1.135) are consid- 
ered as candidates for the kinases involved [ 1,2]. 
TPKI, identical to glycogen synthase kinase (GSK) 3/3 [3], 
phosphorylates native tau in a PHF-like manner [2,3], and is 
involved in B-amyloid-mediated neuronal death [4], suggesting 
that TPKI/GSK3B might be a key enzyme in the disease. 
Native tau is already phosphorylated to some extent, and this 
normal phosphorylation enhanced the abnormal phosphoryla- 
tion by TPKI/GSK3B. TPKII is considered as a candidate for 
the kinases involved in this normal phosphorylation, indicating 
that TPKII regulates the abnormal phosphorylation via normal 
phosphorylation indirectly [5]. Sites phosphorylated by TPKI 
[6] and TPKII [A were occupied significantly by phosphate 
groups in human PHF-tau [8,9] and rat juvenile tau [lo], sug- 
gesting that these TPKs are involved in sprouting [ll] and/or 
neuronal death, which are considered to be two common fea- 
tures in Alzheimer’s disease brain and neonatal brain. 
TPKII is composed of a 30 kDa catalytic subunit and a 23 
kDa regulatory subunit (~23) [2]. The 30 kDa subunit is cyclin- 
dependent kinase (cdk) 5 [12], which was originally known as 
PSSALRE kinase [13] and later named cdk5 because of its 
ability of association with cyclin D [ 141. cDNA cloning [ 151 and 
enzyme purification [16,17] gave the means to search for cdc2- 
related kinases in mammalian brain, which indicated that cdk5 
is the most prominent. 
~23, a partner of cdk5, is regarded as an activator of cdk5, 
because active cdk5 co-eluted with the 23 kDa protein and cdk5 
monomer was inactive [18]. The cdk5 of bovine brain proline- 
directed protein kinase associates with a 25 kDa protein [16], 
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which seems to be identical to p23 although the estimated 
molecular weight is different. Cyclin-dependent kinases are 
known to be active only in complexes with their regulatory 
subunits known as cyclins [19]. cdk5 was reported to associate 
with D-type cyclin in human fibroblasts [14]. In brain, however, 
its regulatory subunit is not a well-known cyclin such as cyclin 
D. p23 is a C-terminal fragment of a novel protein (precursor 
of p23, pre-p23) [181 containing a slight similarity to amino acid 
sequences in the cyclin box of cyclin Dl [20]. The cyclin box 
is important for the interaction with cdcZrelated kinase [21]. 
Considering that the function of cyclin is emphasized as a cell 
cycle promoting activity, p23 should not be called a cyclin 
because the neurons where TPKII exists are terminal differen- 
tiated cells that are out of the cell cycle. It is interesting that 
cdk5 binds to cyclin Dl in fibroblasts [14] and p23 in neurons. 
These accessory proteins may determine the different functions 
of cdk5 in different cells. 
In our previous paper [ 181, the molecular size of pre-p23 was 
unknown because the sequencing was incomplete. Here, we 
show its complete sequence and characterize it further, espe- 
cially the developmental change of its expression. 
2. Materials and methods 
2.1. Materials 
Bovine TPKII was purified by the method described previously [2]. 
The anti-cdk5 antibody was described nreviouslv as an anti-30 kDa 
subunit antibody against peptide 2 [12].- _ 
2.2. Sequencing 
Two cDNA clones, no. 2-l and no.5, were ligated to EcoRI linker 
and inserted into the vector, pUC19. DNA was sequenced by dideoxy- 
mediated sequencing [22]. 
2.3. Northern blot analysis and probes 
Total RNA was prepared from rat brains of various ages and from 
various rat tissues at day 8 postnatally with TRIxol reagents [23]. Using 
magnetic oligo dT beads (Dynabeads; Dynal), poly(A)+ RNA was sep- 
arated from total RNA. Each aliquot of poly(A)+ RNA (1 &lane) was 
separated on a formaldehyde-agarose g l, and blotted to Hybond-N’ 
membranes (Amersham). These blots were hybridized with the follow- 
ing DNA probes prepared by random-primed labelling (Takara): the 
23 kDa subunit and its precursor (probe 1 and 2, respectively, in 
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Fig. 1A); c&5, the EcoRI 1 .l kb fragment of bovine cdk5 cDNA [ 151; 
G3PDH, the EcoRI 1.1 kb fragment of human glycerol 3-phosphate 
dehydrogenase cDNA (Clontech). The blots were analyzed by a 
bioimaging analyzer BAS2000. Expressed amounts of mRNA were 
normalized with respect to the amounts of G3PDH. RNA size was 
measured using a 0.24-9.5 kb RNA ladder (Gibco BRL). With this 
marker, 28 S and 18 S RNAs were estimated to be 4.7 and 1.8 kb, 
respectively. 
2.4. Synthesis ofpeptides andpreparation of antisera against thepeptides 
Peptides were synthesized by the solid-phase method, using a Bio- 
search model 9500 peptide synthesizer. According to the amino acid 
residue number of pre-p23 (Fig. lA,B), the sequence of: (i) pre-p23-N 
is Lys’3-Ser3”-Cys; (ii) p23-N is Lys-Ala*-Vali2’; (iii) p23-C peptide is 
Lysn’-Lyr?‘. The peptides were conjugated with keyhole limpet he- 
mocyanin (KLH). Preparation of antibodies against he peptide-KLH 
conjugants were described previously [12]. 
2.5. Preparation of rat brain extract 
Wistar rat brain was homogenized at 4°C in 2 ~01s. of 10 mM 
Tris-HCl (PH 7.4), 50 mM NaCl, 1 mM EGTA, 1 mM EDTA, 50 mM 
NaF, 10 nM okadaic acid, 50 mM b-glycerophosphate, 1 mM PMSF, 
1 @nl leupeptin, 1 @ml pepstatin, 1 @ml antipain, 0.5 mg/ml 
benzamidine. The homogenate was centrifuged at 15,000 x g for 20 min 
and the supematant retained. 
2.6. Immunoprecipitation 
Immunoglobulin was purified from antisera against p23-N or p23-C 
by the method reported previously [5]. The purified immunoglobulin 
(40 pg) was added to 20 ~1 of protein G-Sepharose 4 fast flow (Pharma- 
cia). Immunoprecipitation was as described previously [24J. The im- 
munoprecipitates were used for measurement of TPKII activity and 
immunoblotting. 
2.7. TPKII-speciJc assay 
TPKII activity in the immunoprecipitate or TPKII fraction was 
measured by the method reported previously [2] using 0.2 mg/ml pro- 
Src peptide [15] as a substrate. 
2.8. Zmnunoblotting 
Polypeptides were separated on SDS-polyacrylamide gels and trans- 
fered to nitrocellulose membranes. Immunoblotting was performed 
with the ABC kit (Vector Laboratories) using 4chloro-1-naphthol 
(Wake) as a chromogen. For crude brain extract, blocking of the 
membrane and reaction with primary antibody were done using Tris- 
buffered saline containing 5% skimmed milk. 
3. Results 
We have previously determined the sequence of p23 which 
started just from the N-terminal residue of ~23. No initiation 
codon was present near this N-terminus. Therefore, further 
sequence analysis of cDNA was undertaken. The overlapping 
sequences of the two independent clones, 2-l (nucleotide - 188 
to +840) and 5 (nucleotide + 117 to + 1130), were identical, and 
the nucleotide sequence and a deduced amino acid sequence are 
shown in Fig. lA, B. The first ATG codon occurred at nucleo- 
tide + 1, and an in-frame termination codon occurred at nucle- 
otide +922. The nucleotide sequence surrounding this ATG 
codon (nucleotide -6 to +4) was in a good agreement with 
Kozak’s context (GCC[A/G]CCAUGG) for efficient transla- 
tion in higher eukaryotes, except for the G at position -5 [25]. 
Thus, we conclude that the first ATG is the actual initiation 
codon. This ATG is followed by a long reading frame (ORF) 
encoding a novel protein composed of 307 amino acids with a 
molecular weight of 33,992 Da. This ORF contains essentially 
the same sequence of p23 downstream of the Ala codon at 
position 99, as reported previously, indicating that the 34 kDa 
protein is a precursor of p23 (pre-p23) and generates p23 by 
cleavage of the Phe-Ala linkage. A single change at +340 from 
G to C was observed when compared to previous results [18]. 
The N-terminal region of pre-p23 lacking p23 is rich in basic 
amino acids residues, but has no bipartite nuclear targeting 
sequence [26], and no destruction box as found in the N-termi- 
nus of G2-M cyclin [27]. By Western blot analysis of the crude 
extracts obtained from postnatal day 4 rat brain using anti-p23- 
N, anti-p23-C or anti-pre-p23-N antibodies, a band of 34 kDa 
was detected, but nothing at the 23 kDa position in every case 
(Fig. 2). At least, a detectable amount of pre-p23 was actually 
present in rat brain. 
Northern blot analysis of poly(A)’ RNA from various rat 
tissues at day 8 postnatally showed that a single pre-p23 mRNA 
was expressed only in the brain, and was not detectable in other 
tissues (Fig. 3), while both mRNAs (1.2 kb and 2.1 kb) of cdk5 
were also expressed at the highest level in brain as reported 
previously [16]. In other tissues tested, the short mRNA was 
expressed at levels lower than observed in brain, whereas the 
long mRNA was detected at levels only slightly above the 
threshold level for detection. 
We have previously suggested that p23 is an activator of cdk5 
in neuronal cells playing a role analogous to cyclin in prolifer- 
ating cells [18] because of the co-existence of p23 and cdk5 in 
the active fraction of TPKII. To reinforce the evidence for this 
suggestion, immunoprecipitates of TPKII with anti-p23 anti- 
bodies were examined (Fig. 4). Purified bovine TPKII was 
immmunoprecipitated either with anti-p23-N or anti-p23-C an- 
tibody. TPKII activity was detected in both precipitates with 
antibodies, while little activity remained in supernatants. By 
Western blotting using the same antibodies and anti-cdk5 anti- 
body, both immunoprecipitates were found to contain cdk5 in 
addition to ~23, indicating that p23 associates with cdk5 to 
form an active complex, that is TPKII. This result proved our 
presumption clearly, and indicated that immunoprecipitation 
with anti-p23 antibody is useful as a specific assay for TPKII 
in tissue extracts. 
It has been reported that phosphorylation of tau in rat brain 
is evident both pre- and postnatally, and is developmentally 
regulated [5]. Northern blot analysis of poly(A)’ RNA from rat 
brains of various ages (Fig. 5A) showed that expression of 
pre-p23 mRNA was most abundant just before and after birth 
(from gestation day 18 to day 1 postnatally) and retained abun- 
dantly in neonatal brain (about 2 weeks). Later, it decreased 
gradually to reach a minimum level in young adult brain (5 
weeks to 4 months) and a slightly increased amount in aged 
adult brain. Although expression of cdk5 mRNA also changed 
in a manner similar to that of pre-p23 mRNA, it decreased only 
about 50% from the highest expression to that in aged adult 
brain. Developmental change of TPKII activity in brain ex- 
tracts was in good agreement with that of the expression of 
pre-p23, but not of cdk5 mRNA (Fig. SB). Considering that 
phosphorylation at TPKII sites of tau is developmentally regu- 
lated, and reached its highest level within the first week postna- 
tally, it is reasonable to conclude that the xpression of pre-p23 
controls the phosphorylation of tau by TPKII in neonatal rat 
brain. 
4. DtseuSion 
We report here that p23 is a regulatory subunit of TPKII and 
is derived from a precursor protein of 34 kDa by cleavage by 
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Fig. 1. Structure of cDNA of bovine pre-p23. (A) Map of the cDNA. The sequence of nucleotides (nt) - 188 to + 1130 was determined. An open reading 
frame is found at nt +l to +924, and indicated by a rectangle. The amino acid sequence of pre-p23 and p23 are found at amino acid (aa) l-307 and 
99-307, respectively. Nucleotide probes 1 and 2 correspond to the regions indicated by black bars. Sequences of synthetic peptides, pre-p23-N, p23-N 
and p23-C, are indicated by open boxes. (B) Sequence ofpre-p23. The nt sequence 29s-970 and aa sequence 99 to 307 were already reported in our 
previous paper [24]. The accession number for the nucleotide and amino acid sequences is X78934 in the EMBL data library. 
an unknown protease at a Phe-Ala linkage to yield the mature to cyclins nor any relationship to any other motif. This result 
p23 (C-terminal) protein. We previously reported that p23 has leads to the conclusion that pre-p23 is not a cyclin even though 
a sequence with a slight similarity to the cyclin box of cyclin D 1, it interacts with cdk5, as does cyclin D of human fibroblasts. 
which might act as the binding site to cdk5 [ 181. The complete Immunoprecipitation of p23 with anti-p23 antibodies co- 
amino acid sequence of the pre-p23 has no additional similarity precipitates cdk5 from preparations of purified TPKII. The 
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Fig. 2. Immunoblot of rat brain extract with anti-p23 and anti-pre-p23 
antisera. 260 mg brain extract of 6-month-old rat was immunoblotted 
with anti-p23-N (1: 30, lanes 1,2), anti-p23-C (1: 15, lanes 3,4) or anti- 
pre-p23-N (1: 50, lanes 5,6). Antiserum was preadsorbed by 0.1 mg/ml 
antigen peptide p23-N (lane 2), p23-C (lane 4) or pre-p23-N (lane 6) for 
15 h at 4°C. Molecular weights of marker proteins are indicated at the 
right. 
interaction between cdk5 and p23 is very strong, not dissociat- 
ing even in the presence of 1 M NaCl (data not shown). We 
have also shown, as before [18], that a complex between cdk5 
and p23 is required for kinase activity of TPKII. The 34 kDa 
protein, pre-p23, can also be found in crude extracts of rat 
brain, but it is unclear whether or not it is in a complex with 
cdk5. 
The following observations lead us to the conclusion that p23 
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1.2- 
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1.3- 
Fig. 3. Northern analysis of pre-p23 and cdk5 mRNA in various organs 
of rat at postnatal day 8. Poly(A)+ RNA was extracted from brain (B), 
salivary gland (Sg), thymus (IX), heart (H), lung (Lg), intestine (I), 
kidney (K), testis (Te) and skeletal muscle (M). 1 pg of RNA was 
hybridized with probe 1 for detection of pre-p23 mRNA (upper), the 
EcoRI fragment of cdk5 cDNA for cdk5 mRNA (middle), and G3PDH 
cDNA as positive control (lower). 
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Fig. 4. Immunoprecipitation ofTPKII with anti-p23 antibodies. TPKII 
(1.9 pmol/min) was immunoprecipitated by anti-p23-N (N, lanes 2 and 
3) or anti-p23-C (C, lanes 4 and 5). TPKII (lane l), supematant (s, lanes 
2 and 4) and precipitate (p, lanes 3 and 5) of immunoprecipitation were 
immunoblotted with anti-cdk5 (1: 30, A), anti-p23-N (1: 30, B) or anti- 
p23-C (1: 30, C). The positions of cdk5 and p23 are indicated at the 
right. Arrowheads indicate the position of light chain of immunoglob- 
ulin co-precipitated and reacted with anti-rabbit immunoglobulin anti- 
body used as the second antibody of the immunoblot. Recovery of 
TPKII is indicated in terms of activity at the bottom. 
is a cdk5 activator: (i) cdk5 monomer alone has little activ- 
ity [18]; (ii) active TPKII is a complex of cdk5 with ~23; 
(iii) expression of pre-p23 changes in parallel with TPKII activ- 
ity in rat brain during development. The cdk5 activator p23 is 
considered to be brain-specific because expression of pre-p23 
specifically occurs in the brain. 
TPKII activity in rat brain extracts was retained at high 
levels within the first week postnatally, and then decreased 
gradually till postnatal week 5, indicating that TPKII is active 
in neonatal rat brain. This result is consistent with the previous 
observation that phosphorylation at TPKII sites of tau reached 
a maximum level within the first week postnatally [5]. There- 
fore, expression of pre-p23, but not of cdk5, controls the ap- 
pearence of TPKII activity which controls the function of 
TPKIVTPKI phosphorylation system in neonatal brain, where 
sprouting of neurite and neuronal cell death occur extensively. 
Actually, TPKI was also shown to be present at a high level in 
neonatal brain [24]. In addition, TPKI was reported to play an 
important role in /Lamyloid-mediated programmed cell death 
in the primary culture of hippocampal cells [4]. A slight increase 
in pre-p23 expression in the aged brain may reflect the involve- 
ment of the TPKIUTPKI phosphorylation system in neuronal 
cell death. 
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Fig. 5. Developmental change of expression of mRNA of cdk5 and pre-p23, and TPKII activity. (A) Total RNA was prepared from rat brain at 
embryonic day 15, 18,20, and postnatal day (d) 1,4,8, week (w) 2,3,4,5, month (m) 3,5,6, and year (y) 1,2. 1 pg of poly(A)+ RNA was subjected 
to Northern analysis. (B) TPKII activities in immunoprecipitates of brain extracts with anti-p23-C are indicated by filled circles. Relative amounts 
of pre-p23 mRNA in (A) were measured and are indicated by open circles. 
Acknowledgements: We thank Dr. K. Sato for synthesis of peptides. We 
also thank Dr. R.J. Crouch MIH. USA) for readine the manuscrint. 
This work was supported by a Grant-in-Aid for Scieitific Research on 
Priority Areas (No. 04268 104) from the Ministry of Education, Science 
and Culture, Japan. 
References 
[l] Ishiguro, K., Ihara, Y., Uchida, T. and Imahori, K. (1988) 
J. B&hem. 104, 319321. 
[2] Ishiguro, K., Takamatsu, M., Tomixawa, K., Omori, A., 
Takahashi, M., Arioka, M., Uchida, T. and Imahori, K. (1992) 
J. Biol. Chem. 267, 10897-10901. 
[3] Ishiguro, K., Shiratsuchi, A., Sato, S., Gmori, A., Arioka,M., 
Kobavashi, S., Uchida, T. and Imahori, K. (1993) FEBS Lett. 325. 
167-1-72. 
[4] Takashima, A., Noguchi, K., Sato, K., Ho&no, T. and Imahori, 
K. (1993) Proc. Natl. Acad. Sci. USA 90. 7789-7793. 
[5] Aribka, ‘M., Tsukamoto, M., Ishiguro, K., Kato. R., Sato, K., 
Imahori, K. and Uchida, T. (1993) J. Neurochem. 60,461468. 
[6] Ishiguro, K., Gmori, A., Takamatsu, M., Sato, K., Arioka, M., 
Uchida, T. and Imahori, K. (1992) Neurosci. Lett. 148,202-206. 
[7] Ishiguro, K., Gmori, A., Sato, K., Tomizawa, K., Imahori, K. and 
Uchida, T. (1991) Neurosci. L&t. 128, 195-198. 
[8] Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, 
M., Titani, K. and Ihara, Y. (1992) J. Biol. Chem. 267, 17047- 
17054. 
PI 
WI 
Pll 
WI 
1131 
P41 
P51 
WI 
D?l 
WI 
;;z; 
WI 
WI 
[231 
Morishima-Kawashima, M., Hasegawa, M., Takio, K., 
Suxuki,M., Yoshida, H., Titani, K. and Ihara, Y. (1994) Neuro- 
biol. Aging (in press). 
Watanabe, A., Hasegawa, M., Suzuki, M., Takio, K., Morishima- 
Kawashima, M., T&i, K., Arai, T., Kosik, K.S. and Ihara, Y. 
(1993) J. Biol. Chem. 268. 25712-25717. 
Ihara; Y. (1988) Brain Res. 459, 138-144. 
Kobayashi, S., ~Ishiguro, K., Gmori, A., Takamatsu, M., Arioka, 
M.. Imahori. K. and Uchida. T. (1993) FEBS L&t. 335. 171-175. 
Meyerson, M., Enders, G.H., Wu, C-L., Su, L.-K., Gorka, C., 
Nelson, C., Harlow, E. and Tsai, L.-H. (1992) EMBO J. 11,2909- 
2917. 
Xiong, Y., Zhang, H. and Beach, D. (1992) Cell 71, 505-514. 
Helhuich, M.R., Pant, H.C., Wada, E. and Battey, J.F. (1992) 
Proc. Natl. Acad. Sci. USA 89, 10867-10871. 
Lew, J., Beaudette, K., Litwin, C.M.E. and Wang, J.H. (1992) 
J. Biol. Chem. 267, 13383-13390. 
Lew, J., Winkfein, R.J., Paudel, H.K. and Wang, J.H. (1992) 
J. Biol. Chem. 267,25922-25926. 
Ishiguro, K., Kobayashi, S., Gmori, A., Takamatsu, M., 
Yonekura, S., Anxai, K., Imahori, K. and Uchida, T. (1994) FEBS 
Lett. 342, 203-208. 
Pines, J. (1993) Trends Biol. Sci. 18, 195-197. 
Lew, D.J.; Duiic, V. and Reed, S.I. (1991) Cell 66, 1197-1206. 
Lees. E.M. and Halow. E. (1993) Mol. Cell. Biol. 13. 1194-1201. 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc: Natl. Acad. 
Sci. USA 74, 5463-5467. 
Chomczynski, P. (1993) Biotechniques 15, 532. 
40 T &hi& et al. IFEBS Letters 3.55 (1994) 35-40 
WI Takahashi, M., Tomizawa, K., Kato, R., Sato, K., Uchida, T., 
Fujita, S.C. and Imahori, K. (1994) J. Neurochem. 63, 245- 
255. 
Kozak, M. (1991) J. Biol. Chem. 266, 19867-19870. 
Robbins, J., Dilworth, SM., Laskey, R.A. and Dingwall, C. (1991) 
Cell 64, 615-623. 
1271 
PI 
1291 
Glotzer, M., Murray, A.W. and Kirschner, M.W. (1991) Nature 
349, 132-138. 
P51 
WI 
Tsai, L.-H., Delalle, I., Caviness Jr., VS., Chae, T. and Harlow, 
E. (1994) Nature 371,419-423. 
Lew, J., Huang, Q.-Q., Qi, Z., Winlcfein, R.J., Aehersold, R., 
Hunt, T. and Wang, J.H. (1994) Nature 371, 423426. 
Note added in proof 
After the submission of this manuscript, we found two reports on the same subject [28,29] as that described here. Several sequences, 
such as those from nt -188 to -136 in the 5’ non-coding region and from 1066 to 1130 in 3’ non-coding region, are not coincident 
with those reported by Lew et al. [29]. 
